


Viral Epidemiology Snapshot: August 7-13, 2022


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV					
<u>Virus</u>	#Tested	#Positive	% Positive		
Flu A	217	0	0.0%		
Flu B	217	0	0.0%		
RSV	215	23	10.7%		
CoV-2 PUI	782	166	21.2%		
CoV-2 Surveillance	453	23	5.1%		

Flu A Subtyping				
2009 H1N1	0			
Seasonal H1	0			
Seasonal H3	0			
No Subtype	0			
Pending subtype	0			

Other Respiratory Viruses						
<u>Virus</u>	#Tested	#Positive	% Positive			
Adenovirus	210	17	8.1%			
Coronavirus 229E	210	0	0.0%			
Coronavirus HKU1	210	1	0.5%			
Coronavirus NL63	210	0	0.0%			
Coronavirus OC43	210	0	0.0%			
Metapneumovirus	210	2	1.0%			
Rhinovirus/Enterovirus	210	58	27.6%			
Parainfluenza 1	210	9	4.3%			
Parainfluenza 2	210	0	0.0%			
Parainfluenza 3	210	4	1.9%			
Parainfluenza 4	210	3	1.4%			





This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/20) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.